Aldosterone receptor antagonists for heart failure: current status, future indications

Cleve Clin J Med. 2006 Mar;73(3):257-60, 264-8. doi: 10.3949/ccjm.73.3.257.

Abstract

Many patients with heart failure should receive an aldosterone receptor antagonist, ie, either spironolactone (Aldactone) or the newer agent eplerenone (Inspra)--in addition to an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) or both, and a beta-blocker. We review the evidence and indications.

Publication types

  • Review

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Eplerenone
  • Forecasting
  • Heart Failure / drug therapy*
  • Humans
  • Mineralocorticoid Receptor Antagonists* / therapeutic use*
  • Practice Guidelines as Topic
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Spironolactone / analogs & derivatives
  • Spironolactone / therapeutic use

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Mineralocorticoid Receptor Antagonists
  • Spironolactone
  • Eplerenone